Review: From therapy to experimental model: A hundred years of endotoxin administration to human subjects

Journal of Endotoxin Research

Volumn 13, Issue 5, 2007, Pages 251-279

  Bahador, Marjan ^b   Cross, Alan S ^a  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

^b NONE   (United States)

Author keywords

Endotoxin; Human subjects

Indexed keywords

4 [4 (4 FLUOROPHENYL) 1 (3 PHENYLPROPYL) 5 (4 PYRIDINYL) 1H IMIDAZOL 2 YL] 3 BUTYN 1 OL; ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; ARSENIC; BACTERIAL TOXIN; BACTERIUM LIPOPOLYSACCHARIDE; COLEY TOXIN; CYTOKINE; DOBUTAMINE; DORAMAPIMOD; E 5531; E 5564; ENALAPRIL; ENDOTOXIN; ERITORAN; HEPARIN; HYDROCORTISONE; IBUPROFEN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LOW MOLECULAR WEIGHT HEPARIN; MERCURIC CHLORIDE; NICOTINAMIDE; PARACETAMOL; PLACEBO; PREDNISOLONE; SALMONELLA ENDOTOXIN; SIMVASTATIN; STEROID; TISSUE FACTOR PATHWAY INHIBITOR; TOXIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINEURIN; NONSTEROID ANTIINFLAMMATORY AGENT;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ASYSTOLE; BLOOD CLOTTING DISORDER; BLOOD TOXICITY; BRADYCARDIA; CANCER; CELLULAR IMMUNITY; CHILL; CLINICAL RESEARCH; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ENDOTOXEMIA; ERYSIPELAS; EXPERIMENTAL MODEL; FATIGUE; FLU LIKE SYNDROME; HEMOSTASIS; HUMAN; HYPERTHERMIC THERAPY; HYPOTENSION; IMMUNOMODULATION; INFECTION; INFLAMMATION; KIDNEY FUNCTION; LIVER FUNCTION; LOW DRUG DOSE; MALAISE; MALARIA; MYALGIA; NAUSEA; NEUROSYPHILIS; NONCARDIOGENIC LUNG EDEMA; NONHUMAN; REVIEW; SEPSIS; SHOCK; SIDE EFFECT; SINGLE DRUG DOSE; SYNCOPE; VOMITING; BLOOD CLOTTING; DRUG EFFECT; DRUG TOXICITY; ENDOTHELIUM CELL; IMMUNOLOGY; LEUKOCYTE; METABOLISM;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD COAGULATION; CYTOKINES; DRUG TOXICITY; ENDOTHELIAL CELLS; ENDOTOXINS; HUMANS; LEUKOCYTES;

EID: 35848936089     PISSN: 09680519     EISSN: None     Source Type: Journal    
DOI: 10.1177/0968051907085986     Document Type: Review

References (141)

1. Dinarello CA, Wolff SM Current Concepts: Fever. Scope Publication, Upjohn, 1980.
2. Wolff SM Biological effects of bacterial endotoxins in man. J Infect Dis 1973; 128: S259-S264.
3. Lowry SF Human endotoxemia: A model for mechanistic insight and therapeutic targeting. Shock 2005; 24 (Suppl. 1): 94-100.
4. Burrell R. Human responses to bacterial endotoxin. Circ Shock 1994; 43: 137-153.
5. Stolley PD Fever therapy: Lessons from the history and efficacy of malariotherapy. In: Mackowiak PA. (ed) Fever: Basic Mechanisms and Management, 2nd edn. Philadelphia, PA: Lippincott-Raven, 1997; 331-335.
6. Ellingson HV, Clark PF The influence of artificial fever on mechanisms of resistance. J Immunol 1942; 43: 65-81.
7. Rodbard D., Rodbard HW, Rodbard S. Temperature: A critical factor determining localization and natural history of infectious, metabolic, and immunological diseases. Perspect Biol Med 1980; 23: 439-474.
8. Morgan HR Immunologic properties of an antigenic material isolated from Eberthella typhosa. J Immunol 1941; 41: 161.
9. Favorite GO, Morgan HR Effects produced by the intravenous injection in man of a toxic antigenic material derived from Eberthella typhosa: clinical, hematological, chemical and serological studies. J Clin Invest 1942; 21: 589-599.
10. Morgan HR Tolerance to the toxic action of somatic antigens of enteric bacilli. J Immunol 1948: 59: 129.
11. Neva FA, Morgan HR Tolerance to the action of endotoxins of enteric bacilli in patients convalescent from typhoid and paratyphoid fevers. J Lab Clin Med 1950; 35: 911-922.
12. Heyman A., Beeson PB Influence of various disease states upon the febrile response to intravenous injection of typhoid pyrogen. J Lab Clin Med 1949; 34: 1400-1403.
13. Beeson PB Tolerance to bacterial pyrogens. I. Factors influencing its development. J Exp Med 1947; 86: 29.
14. Morgan HR Resistance to the action of the endotoxins of enteric bacilli in man. J Clin Invest 1948; 27: 706-709.
15. Beeson PB Tolerance to bacterial pyrogens. II. Role of the reticuloendothelial system. J Exp Med 1947; 86: 39.
16. Shwartzman G. Phenomenon of Local Tissue Reactivity. New York: Paul Hoeber, 1937.
17. Thomas L., Good RA Studies on generalized Shwartzman reaction. General observations concerning phenomenon. J Exp Med 1952; 96: 605-624.
18. Thomas L. Mechanism involved in tissue damage by endotoxins of Gram-negative bacteria. In: Lawrence HS. (ed) Cellular and Humoral Aspects of the Hypersensitive States. New York: Hoeber-Harper, 1959; 1-667.
19. Davis CE, Arnold K. Role of meningococcal endotoxin in meningococcal purpura. J Exp Med 1974; 149: 159-171.
20. Wolff SM, Rubenstein M., Mulholland JH, Alling DW Comparison of hematologic and febrile response to endotoxin in man. Blood 1965; 26: 190-201.
21. Michie HR, Manogue KR, Spriggs DR et al. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 1988; 318: 1481-1486.
22. Granowitz EV, Porat R., Gelfand JA, Wolff SM, Dinarello CA Administration of low-dose endotoxin to healthy humans increases C5a binding to circulating neutrophils. J Infect Dis 1994; 169: 480-482.
23. Granowitz EV, Porat R., Orencole SF et al. Granulocyte-macrophage colony stimulating factor synthesis during experimental endotoxemia in humans. J Infect Dis 1992; 166: 1204-1205.
24. Granowitz EV, Santos AA, Poutsiaka DD et al. Production of interleukin-1 receptor antagonist during experimental endotoxemia. Lancet 1991; 338: 1423-1424.
25. Kimball HR, Melmon ML, Wolff SM Endotoxin-induced kinin production in man. Proc Soc Exp Biol Med 1972; 139: 1078-1082.
26. Greisman SE, Hornick RB, Carozza Jr FA, Woodward TE. The role of endotoxin during typhoid fever and tularemia in man. I. Acquisition of tolerance to endotoxin. J Clin Invest 1963; 42: 1064-1075.
27. Greisman SE, Wagner HN, Iio M., Hornick RB Mechanisms of endotoxin tolerance. II. Relationship between endotoxin tolerance and reticuloendothelial system phagocytic activity in man. J Exp Med 1964; 119: 241-264.
28. Greisman SE, Hornick RB, Wagner Jr HN, Woodward WE, Woodward TE The role of endotoxin during typhoid fever and tularemia in man. IV. The integrity of the endotoxin tolerance mechanism during infection. J Clin Invest 1969; 48: 613-664.
29. Greisman SE, Woodward WE Mechanisms of endotoxin tolerance. III The refractory state during continuous intravenous infusion of endotoxin. J Exp Med 1965; 121: 911-933.
30. Hall SS A Commotion in the Blood: Life, Death and the Immune System. New York: Henry Holt, Chapters 1-5.
31. Beebe SP, Tracy M. The treatment of experimental tumors with bacterial toxins. JAMA 1907; 49: 1493-1498.
32. Hartwell Jl, Shear Mj, Adams Jr Jr. Chemical treatment of tumors. VII. Nature of hemorrhage-producing fraction from Serratia marcescens (Bacillus prodigiosus) culture filtrate. J Natl Cancer Inst 1943; 4: 107-122.
33. Carswell EA, Old LJ, Kassel RL, Green S., Fiore N., Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975; 72: 3666-3670.
34. Westphal O., Luderitz O., Bister E. Uber die extraction von bacterien mit phenol/wasser. Z Naturforsch Teil B 1952; 7: 148.
35. Rudbach JA, Akiya FI, Elin RJ et al. Preparation and properties of a national reference endotoxin. J Clin Microbiol 1976; 3: 21-25.
36. Suffredini AF, Hochstein HD, McMahon FG Dose-related inflammatory effects of intravenous endotoxin in humans: Evaluation of a new clinical lot of Escherichia coli O:113 endotoxin. J Infect Dis 1999; 179: 1278-1282.
37. Poole S., Mussett MV The International Standard for Endotoxin: evaluation in an international collaborative study. J Biol Stand 1989; 17: 161-171.
38. Williams WV, Fullerton T., Fox JC, Enslin MB, Murray L., Jorkasky D. Asystole following endotoxin administration. J Endotoxin Res 2000; 6: 303-306.
39. van Eijk Ltgj, Pickkers P., Smits P., Bouw Mpwjm, van der Hoeven JG Severe vagal response after endotoxin administration in humans. Intensive Care Med 2004; 30: 2279-2281.
40. a. Taveira da Silva AM, Kaulbach HC, Chuidian FS, Lambert DR, Suffredini AF, Danner RL Shock and multiple-organ dysfunction after self-administration of Salmonella endotoxin. N Engl J Med 1993; 328: 1457-1460.
41. Copeland S., Warren HS, Lowry SF, Calvano SE, Remick D. Acute inflammatory response to endotoxin in mice and humans; Inflammation and the Host Response to Injury Investigators. Clin Diagn Lab Immunol 2005; 12: 60-67.
42. Coyle SM, Calvano SE, Lowry SF Gender influences in vivo human responses to endotoxin. Shock 2006; 26: 538-543.
43. van Eijk LT, Dorresteijn MJ, Smits P., van der Hoeven JG, Netea MG, Pickkers P. Gender differences in the innate immune response and vascular reactivity following the administration of endotoxin to human volunteers. Crit Care Med 2007; 35: 1464-1469.
44. Krabbe KS, Bruunsgaard H., Hansen CM et al. Ageing is associated with a prolonged fever response in human endotoxemia. Clin Diagn Lab Immunol 2001; 8: 333-338.
45. Suffredini AF, Fromm RE, Parker MM et al. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 1989; 321: 280-287.
46. van Bockel EA, Tulleken JE, Muller Kobold AC et al. Cardiac troponin I release and cytokine response during experimental human endotoxaemia. Intensive Care Med 2003; 29: 1598-1600.
47. Pleiner J., Heere-Ress E., Langenberger H. et al. Adrenoceptor hyporeactivity is responsible for Escherichia coli endotoxin-induced acute vascular dysfunction in humans. Arterioscler Thromb Vasc Biol 2002; 22: 95-100.
48. Martich GD, Parker MM, Cunnion RE, Suffredini AF Effects of ibuprofen and pentoxifylline on the cardiovascular response of normal humans to endotoxin. J Appl Physiol 1992; 73: 925-931.
49. Jellema WT, Veerman DP, De Winter RJ et al. In vivo interaction of endotoxin and recombinant bactericidal/permeability-increasing protein (rBPI23): Hemodynamic effects in a human endotoxemia model. J Lab Clin Med 2002; 140: 228-235.
50. 23) attenuates endotoxin-induced circulatory changes in humans. J Inflamm 1995; 45: 193-206.
51. Suffredini AF, Shelhamer JH, Neumann RD, Brenner M., Baltaro RJ, Parrillo JE Pulmonary and oxygen transport effects of intravenously administered endotoxin in normal humans. Am Rev Respir Dis 1992; 145: 1398-1403.
52. a. Boujooukos AJ, Martich GD, Supinski E., Suffredini AF Compartmentalization of the acute cytokine response in humans after intravenous endotoxin administration. J Appl Physiol 1993; 74: 3027-3033.
53. Smith PD, Suffredini AF, Allen JB, Wahl LM, Parrillo JE, Wahl SM Endotoxin administration to humans primes alveolar macrophages for increased production of inflammatory mediators. J Clin Immunol 1994; 14: 141-148.
54. Pollard V., Prough DS, Deyo DJ et al. Cerebral blood flow during experimental endotoxemia in volunteers. Crit Care Med 1997; 25: 1700-1706.
55. Pollmacher T., Mullington J., Korth C. et al. Diurnal variations in the human host response to endotoxin. J Infect Dis 1996; 174: 1040-1045.
56. Krabbe KS, Reichenberg A., Yirmiya R., Smed A., Pedersen BK, Bruunsgaard H. Low-dose endotoxemia and human neuropsychological functions. Brain Behav Immun 2005; 19: 453-460.
57. Reichenberg A., Yirmiya R., Schuld A. et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 2001; 58: 445-452.
58. Catania A., Suffredini AF, Lipton JM Endotoxin causes release of alpha-melanocyte-stimulating hormone in normal human subjects. Neuroimmunomodulation 1995; 2: 258-262.
59. Jorgensen VL, Ibsen M., Andressen L., Schulzke JD, Perner A. Effects of endotoxaemia on markers of permeability, metabolism and inflammation in the large bowel of healthy subjects. Acta Anaesthesiol Scand 2007; 51: 1085-1092.
60. Pastor RO, Lopez San Roman A, Albeniz Arbizu E, de la Hera Martinez A, Ripoli Sevillano E, Albillos Martinez A. Serum lipopolysaccharide-binding protein in endotoxemic patients with inflammatory bowel disease. Inflamm Bowel Dis 2007; 13: 269-277.
61. Sharma R., Tepas 3rd JJ, Hudak ML et al. Neonatal gut barrier and multiple organ failure: Role of endotoxin and proinflammatory cytokines in sepsis and necrotizing enterocolitis. J Pediatr Surg 2007; 42: 454-461.
62. Heemskerk S., Pickkers P., Bouw Mpwjm et al. Upregulation of renal inducible nitric oxide synthase during human endotoxemia and sepsis is associated with proximal tubule injury. Clin J Am Soc Nephrol 2006; 1: 853-862.
63. Schuld A., Mullington J., Friess E. et al. Changes in dehydroepiandrosterone (DHEA) and DHEA-sulfate plasma levels during experimental endotoxinemia in healthy volunteers. J Clin Endocrinol Metab 2000; 85: 4624-4629.
64. Calvano SE, Barber AE, Hawes AS, de Riesthal HF, Coyle SM, Lowry SF Effect of combined cortisol-endotoxin administration on peripheral blood leukocyte counts and phenotype in normal humans. Arch Surg 1992; 127: 181-186.
65. van der Poll T., Coyle SM, Barbosa K., Braxton CC, Lowry SF Epinephrine inhibits tumor necrosis factor-α and potentiates interleukin 10 production during human endotoxemia. J Clin Invest 1996; 97: 713-719.
66. van der Poll T., Barber AE, Coyle SM, Lowry SF Hypercortisolemia increases plasma interleukin-10 concentrations during human endotoxemia - A clinical research study. J Clin Endocrinol Metab 1996; 81: 3604-3606.
67. de Kruif MD, Lemaire LC, Giebelen IA et al. Prednisolone dose-dependently influences inflammation and coagulation during human endotoxemia. J Immunol 2007; 178: 1845-1851.
68. van der Poll T., Van Zee KJ, Endert E. et al. Interleukin-1 receptor blockade does not affect endotoxin-induced changes in plasma thyroid hormone and thyrotropin concentrations in man. J Clin Endocrinol Metab 1995; 80: 1341-1346.
69. Fong Y., Marano MA, Mldawer LL et al. The acute splanchnic and peripheral tissue metabolic response to endotoxin in humans. J Clin Invest 1990; 85: 1896-1904.
70. Agwunobi AO, Reid C., Maycock P., Little RA, Carlson GL Insulin resistance and substrate utilization in human endotoxemia. J Clin Endocrinol Metab 2000; 85: 3770-3778.
71. Bornstein SR, Preas HL, Chrousos GP, Suffredini AF Circulating leptin levels during acute experimental endotoxemia and antiinflammatory therapy in humans. J Infect Dis 1998; 178: 887-890.
72. Keller P., Moller K., Krabbe KS, Pedersen BK Circulating adiponectin levels during human endotoxaemia. Clin Exp Immunol 2003; 134: 107-110.
73. Vesali RF, Klaude M., Rooyackers O., Wernerman J. Amino acid metabolism in leg muscle after an endotoxin injection in healthy volunteers. Am J Physiol 2005; 288: E360-E364.
74. Kemna E., Pickkers P., Nemeth E., van der Hoeven H., Swinkels D. Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood 2005; 106: 1864-1866.
75. Gaetke LM, McClain CJ, Talwalkar RT, Shedlofsky SI Effects of endotoxin on zinc metabolism in human volunteers. Am J Physiol 1997; 272: E952-E956.
76. Hesse DG, Tracey KJ, Fong Y. et al. Cytokine appearance in human endotoxemia and primate bacteremia. Surg Gynecol Obstet 1988; 166: 147-153.
77. Cross AS, Opal SM, Sadoff JC, Gemski P. Choice of bacteria in animal models of sepsis. Infect Immun 1993; 61: 2741 - 2747.
78. Cannon JG, Tompkins RG, Gelfand JA et al. Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis 1990; 161: 79-84.
79. Meisner M., Muller V., Khakpour Z., Toegel E., Redl H. Induction of procalcitonin and proinflammatroy cytokines in an anhepatic baboon endotoxin shock model. Shock 2003; 19: 187-190.
80. Koopmans R., Hoek FJ, van Deventer SJ, van der Poll T. Model for whole body production of tumour necrosis factor-alpha in experimental endotoxaemia in healthy subjects. Clin Sci (Lond) 1994; 87: 459-465.
81. van der Poll T., Calvano SE, Kumar A. et al. Endotoxin induces downregulation of tumor necrosis factor receptors on circulating monocytes and granulocytes in humans. Blood 1995; 86: 2754-2759.
82. Jansen J., van der Poll T., Levi M. et al. Inhibition of the release of soluble tumor necrosis factor receptors in experimental endotoxemia by an anti-tumor necrosis factor-alpha antibody. J Clin Immunol 1995; 15: 45-50.
83. van der Poll T., van Deventer SJ, ten Cate H., Levi M., ten Cate JW Tumor necrosis factor is involved in the appearance of interleukin-1 receptor antagonist in endotoxemia J Infect Dis 1994; 169: 665-667.
84. van der Poll T., van Deventer SJ, Buller HR, Sturk A., ten Cate JW Comparison of the early dynamics of systemic prostacyclin release after administration of tumor necrosis factor and endotoxin to healthy humans. J Infect Dis 1991; 164: 599-601.
85. von der Mohlen MA, van der Poll T., Jansen J., Levi M., van Deventer SJ Release of bactericidal/permeability-increasing protein in experimental endotoxemia and clinical sepsis. Role of tumor necrosis factor. J Immunol 1996; 156: 4969-4973.
86. van der Poll T., Coyle SM, Levi M. et al. Effect of a recombinant dimeric tumor necrosis factor receptor on inflammatory responses to intravenous endotoxin in normal humans. Blood 1997; 89: 3727-3734.
87. Fong Y., Moldawer LL, Marano M. et al. Endotoxemia elicits increased circulating beta 2-IFN/IL-6 in man. J Immunol 1989; 142: 2321-2324.
88. Panacek EA, Marshall JC, Albertson TE et al. Monoclonal Anti-TNF: A Randomized Controlled Sepsis Study Investigators. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med 2004; 32: 2173-2182.
89. Reinhart K., Menges T., Gardlund B. et al. Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory responses during severe sepsis: The RAMSES Study. Crit Care Med 2001; 29: 765-769.
90. Fisher Jr CJ, Opal SM, Dhainaut JF et al. Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group. Crit Care Med 1993; 21: 318-327.
91. Marsik C., Halama T., Cardona F., Schlifke I., Mittermayer F., Jilma B. Endotoxemia enhances expression of the signaling receptor (GP130) on protein and molecular level. Clin Immunol 2005; 114: 293-298.
92. Pajkrt D., Manten A., van der Poll T. et al. Modulation of cytokine release and neutrophil function by granulocyte colony-stimulating factor during endotoxemia in humans. Blood 1997; 90: 1415-1424.
93. Dekkers P., Juffermans N., Hove T. et al. Granulocyte colonystimulating factor receptors on granulocytes are down-regulated after endotoxin administration to healthy human. J Infect Dis 2000; 181: 2067-2070.
94. Endler G., Marsik C., Joukhadar C. et al. The interleukin-6 G(-174)C promoter polymorphism does not determine plasma interleukin-6 concentrations in experimental endotoxemia in humans. Clin Chem 2004; 50: 195-200.
95. Kovar FM, Marsik C., Jilma B. et al. The fibrinogen -148 C/T polymorphism influences inflammatory response in experimental endotoxemia in vivo. Thromb Res 2007; 120: 727-731.
96. Kovar FM, Marski C., Cvitko T., Wagner OF, Jilma B., Endler G. The tumor necrosis factor alpha -308 G/A polymorphism does not influence inflammation and coagulation response in human endotoxemia. Shock 2007; 27: 238-241.
97. Granowitz EV, Santos AA, Poutsiaka DD et al. Production of interleukin-1-receptor antagonist during experimental endotoxaemia. Lancet 1991; 338: 1423-1424.
98. Weijer S., Lauw FN, Branger J., van den Blink B., van der Poll T. Diminished interferon-gamma production and responsiveness after endotoxin administration to healthy humans. J Infect Dis 2002; 186: 1748-1753.
99. Cavaillon JM, Munoz C., Fitting C., Misset B., Carlet J. Circulating cytokines: The tip of the iceberg? Circ Shock 1992; 38: 145-152.
100. Prabhakar U., Conway TM, Murdock P. et al. Correlation of protein and gene expression profiles of inflammatory proteins after endotoxin challenge in human subjects. DNA Cell Biol 2005; 24: 410-431.
101. Munoz C., Misset B., Fitting C., Bleriot JP, Carlet J., Cavaillon JM Dissociation between plasma and monocyte-associated cytokines during sepsis. Eur J Immunol 1991; 21: 2177-2184.
102. Sprong T., Pickkers P., Geurts-Moespot A. et al. Macrophage migration inhibitory factor (MIF) in meningococcal septic shock and experimental human endotoxemia. Shock 2007; 27: 482-487.
103. Olszyna DP, Pajkrt D., Lauw FN, van Deventer SJ, van der Poll T. Interleukin 10 inhibits the release of CC chemokines during human endotoxemia. J Infect Dis 2000; 181: 613-620.
104. Pajkrt D., Camoglio L., Tiel-van Buul MC et al. Attenuation of proinflammatory response by recombinant human IL-10 in human endotoxemia: Effect of timing of recombinant human IL-10 administration. J Immunol 1997; 158: 3971-3977.
105. Lauw FN, Pajkrt D., Hack CE, Kurimoto M., van Deventer SJ, van der Poll T. Proinflammatory effects of IL-10 during human endotoxemia. J Immunol 2000; 165: 2783-2789.
106. Olszyna DP, Prins JM, Dekkers PE et al. Sequential measurements of chemokines in urosepsis and experimental endotoxemia. J Clin Immunol 1999; 19: 399-405.
107. Martich GD, Danner RL, Ceska M., Suffredini AF Detection of interleukin-8 and tumor necrosis factor in normal humans after intravenous endotoxin: The effect of anti-inflammatory agents. J Exp Med 1991; 173: 1021-1024.
108. Heesen M., Renckens R., de Vos AF, Kunz D., van der Poll T. Human endotoxemia induces down-regulation of monocyte CC chemokine receptor 2. Clin Vaccine Immunol 2006; 13: 156-159.
109. Marsik C., Mayr F., Cardona F., Derhaschnig U., Wagner OF, Jilma B. Endotoxaemia modulates Toll-like receptors on leukocytes in humans. Br J Haematol 2003; 121: 653-656
110. Calvano JE, Bowers DJ, Coyle SM et al. Response to systemic endotoxemia among humans bearing polymorphisms of the Toll-like receptor 4 (hTLR4). Clin Immunol 2006; 121: 186-190.
111. Knapp S., Gibot S., de Vos A., Versteeg HH, Colonna M., van der Poll T. Expression patterns of surface and soluble triggering receptor expressed on myeloid cells-1 in human endotoxemia. J Immunol 2004; 173: 7131-7134.
112. van der Meer W., Pickkers P., Scott CS, van der Hoeven JG, Gunnewiek J. Hematological indices, inflammatory markers and neutrophil CD64 expression: Comparative trends during experimental human endotoxemia. J Endotoxin Res 2007; 13: 94-100.
113. Dekkers PE, Juffermans NP, ten Hove T., de Jonge E., van Deventer SJ, van der Poll T. Endotoxin down-regulates monocyte and granulocyte interleukin-6 receptors without influencing gp130 expression in humans. J Infect Dis 2000; 181: 1055-1061.
114. Calvano SE, Thompson WA, Marra MN et al. Changes in polymorphonuclear leukocyte surface and plasma bactericidal/permeability-increasing protein and plasma lipopolysaccharide binding protein during endotoxemia or sepsis. Arch Surg 1994; 129: 220-226.
115. Dekkers PE, ten Hove T., te Velde AA, van Deventer SJ, van Der Poll T. Upregulation of monocyte urokinase plasminogen activator receptor during human endotoxemia. Infect Immun 2000; 68: 2156-2160.
116. Florquin S., van den Berg JG, Olszyna DP et al. Release of urokinase plasminogen activator receptor during urosepsis and endotoxemia. Kidney Int 2001; 59: 2054-2061.
117. Ostrowski SR, Plomgaard P., Fischer CP et al. Interleukin-6 infusion during human endotoxaemia inhibits in vitro release of the urokinase receptor from peripheral blood mononuclear cells. Scand J Immunol 2005; 61: 197-206.
118. Wilson M., Blum R., Dandona P., Mousa S. Effects in humans of intravenously administered endotoxin on soluble cell-adhesion molecules and inflammatory markers: A model of human diseases. Clin Exp Pharmacol Physiol 2001; 28: 376-380.
119. Soop A., Albert J., Weitzberg E., Bengtsson A., Lundberg JO, Sollevi A. Complement activation, endothelin-1 and neuropeptide Y in relation to the cardiovascular response to endotoxin-induced systemic inflammation in healthy volunteers. Acta Anaesthesiol Scand 2004; 48: 74-81.
120. van Eijk LT, Pickkers P., Smits P., van den Broek W., Bouw MP, van der Hoeven JG Microvascular permeability during experimental human endotoxemia: An open intervention study. Crit Care 2005; 9: R157-R164.
121. van Eijk LT, Nooteboom A., Hendriks T. et al. Plasma obtained during human endotoxemia increases endothelial albumin permeability in vitro. Shock 2006; 25: 358-362.
122. Mayr FB, Spiel AO, Leitner JM, Firbas C., Sieghart W., Jilma B. Effects of low dose endotoxemia on endothelial progenitor cells in humans. Atherosclerosis 2007; 195: E202-e206.
123. Krabbe KS, Bruunsgaard H., Qvist J. et al. Activated T lymphocytes disappear from circulation during endotoxemia in humans. Clin Diagn Lab Immunol 2002; 9: 731-735.
124. Lauw FN, Simpson AJ, Hack CE et al. Soluble granzymes are released during human endotoxemia and in patients with severe infection due to Gram-negative bacteria. J Infect Dis 2000; 182: 206-213.
125. Pugin J., Widmer MC, Kossodo S., Liang CM, Preas 2nd HL, Suffredini AF. Human neutrophils secrete gelatinase B in vitro and in vivo in response to endotoxin and proinflammatory mediators. Am J Respir Cell Mol Biol 1999; 20: 458-464.
126. Albert J., Radomski A., Soop A., Sollevi A., Frostell C., Radomski MW Differential release of matrix metalloproteinase-9 and nitric oxide following infusion of endotoxin to human volunteers. Acta Anaesthesiol Scand 2003; 47: 407-410.
127. Grobmyer SR, Barie PS, Nathan CF et al. Secretory leukocyte protease inhibitor, an inhibitor of neutrophil activation, is elevated in serum in human sepsis and experimental endotoxemia. Crit Care Med 2000; 28: 1276-1282.
128. van den Blink B., Branger J., Weijer S., Deventer SH, van der Poll T., Peppelenbosch MP Human endotoxemia activates p38 MAP kinase and p42/44 MAP kinase, but not c-Jun N-terminal kinase. Mol Med 2001; 7: 755-760.
129. Branger J., van den Blink B., Weijer S. et al. Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. J Immunol 2002; 168: 4070-4077.
130. Fijen JW, Zijlstra JG, De Boer P. et al. Suppression of the clinical and cytokine response to endotoxin by RWJ-67657, a p38 mitogen-activated protein-kinase inhibitor, in healthy human volunteers. Clin Exp Immunol 2001; 124: 16-20.
131. Dekkers PE, Lauw FN, ten Hove T. et al. The effect of a metalloproteinase inhibitor (GI5402) on tumor necrosis factor-alpha (TNF-alpha) and TNF-alpha receptors during human endotoxemia. Blood 1999; 94: 2252-2258.
132. Verbon A., Dekkers PE, ten Hove T. et al. IC14, an anti-CD14 antibody, inhibits endotoxin-mediated symptoms and inflammatory responses in humans. J Immunol 2001; 166: 3599-3605.
133. Spek CA, Verbon A., Aberson H. et al. Treatment with an anti-CD14 monoclonal antibody delays and inhibits lipopolysaccharide-induced gene expression in humans in vivo. J Clin Immunol 2003; 23: 132-140.
134. Pajkrt D., Doran JE, Koster F. et al. Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J Exp Med 1996; 184: 1601-1618.
135. Erikstrup C., Ullum H., Pedersen BK Short-term simvastatin treatment has no effect on plasma cytokine response in a human in vivo model of low-grade inflammation. Clin Exp Immunol 2006; 144: 94-100.
136. van der Poll T., Braxton CC, Coyle SM et al. Effect of hypertriglyceridemia on endotoxin responsiveness in humans. Infect Immun 1995; 63: 3396-3400.
137. Li N., Soop A., Sollevi A., Hjemdahl P. Multi-cellular activation in vivo by endotoxin in humans - limited protection by adenosine infusion. Thromb Haemost 2000; 84: 381-387.
138. Lemaire LC, de Kruif MD, Giebelen IA, Levi M., van der Poll T., Heesen M. Dobutamine does not influence inflammatory pathways during human endotoxemia. Crit Care Med 2006; 34: 1365-1371.
139. Graninger M., Marsik C., Dukic T., Wagner OF, Blann AD, Jilma B. Enalapril does not alter adhesion molecule levels in human endotoxemia. Shock 2003; 19: 448-451.
140. Soop A., Albert J., Weitzberg E., Bengtsson A., Nilsson CG, Sollevi A. Nicotinamide does not influence cytokines or exhaled NO in human experimental endotoxaemia. Clin Exp Immunol 2004; 135: 114-118.
141. Spinas GA, Bloesch D., Keller U., Zimmerli W., Cammisuli S. Pretreatment with ibuprofen augments circulating tumor necrosis factor-alpha, interleukin-6, and elastase during acute endotoxinemia. J Infect Dis 1991; 163: 89-95.